Skip to content

Stellate Ganglionic Block Versus Stellate Ganglionic Block Plus Pecs II Block for Mastectomy Pain

Stellate Ganglionic Block Versus Combined Stellate Ganglionic Block and Modified Pectoral Nerve Block in Treatment of Post Mastectomy Pain Syndrome.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02641951
Enrollment
40
Registered
2015-12-30
Start date
2015-11-30
Completion date
2016-07-31
Last updated
2016-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Mastectomy Pain Syndrome, After Breast Surgery

Brief summary

Post mastectomy pain syndrome result from surgical damage to the intercostobrachial nerve, the lateral cutaneous branch of the second intercostal nerve that is often resected at mastectomy. result from surgical damage to the intercostobrachial nerve, the lateral cutaneous branch of the second intercostal nerve that is often resected at mastectomy, A second version of the pectoral nerve block is described, called ''modified Pecs block'' or Pecs block type II. This novel approach aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI and the long thoracic nerve. These nerves need to be blocked to provide complete analgesia during breast surgery

Detailed description

The aim of this study is to evaluate the efficacy of ultrasound guided stellate ganglionic block alone versus stellate ganglionic block plus pecs II block in management of chronic postmastectomy pain ,patient will be trained to use visaual analog scale to describe their pain range of movement will be assessed using manual geniometry at post procedure visits at one month ,3 months and 6 months procedures in each group will done using ultrasound guidance mixture will be used. All patients will be informed about the procedure and its possible consequences after detailed explanation of protocol of this study. Written informed consents will be obtained before the procedure. With each block, an intravenous cannula will be inserted and secured. All suitable resuscitation equipment and drugs will be available. Vital signs (heart rate, blood pressure, and oxygen saturation) will be monitored throughout the procedure and up to 1 hour after the block performance. Midazolam 0.02 ug/kg will be administered intravenously as premedication. Brief evaluation will be done for all patients with regard to their systemic diseases, general condition, and coagulation status. All patients will be familiar with the use of 10-cm visual analogue scale score (VAS) identifying 0 as no pain and 10 as worst imaginable pain.Basal assessment of range of movement for abduction ,external rotation ,and forward flextion using manual geniometry and patients will be asked to complete Quality of life questionnaire

Interventions

OTHERStellate ganglionic block

Ultrasound guided stellate ganglionic block

Ultrasound guided Pecs II block

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists physical status III or IV. * Patients having irradiating pain of anterior chest wall and axilla after breast surgery. * Patients having irradiating pain of ipsilateral arm after breast surgery * Pain not responding to conservative treatment * Pain persisting for more than 3 month

Exclusion criteria

* Local skin infection * Coagulation or blood disease * Pregnancy * Postpartum or lactating females * Allergy to the study medications. * Severely altered consciousness level. * Psychiatric disorder * Drug abuse * Spine or chest wall deformities

Design outcomes

Primary

MeasureTime frameDescription
Pain scoresfor six months after the procedure100 mm- visual analog pain scale

Secondary

MeasureTime frameDescription
The range of motion of the glenohumeral jointfor six months after the procedureImprovements in the range of motion of the glenohumeral joint, which included forward extension and external rotation will be recorded using scoring system score 0 to 9 for some movements range and 0 to 160 for others
The quality of life scorefor six months after the procedureThe quality of life will be assessed using the score QOLSF 36

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026